In This Article:
As you might know, Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) last week released its latest quarterly, and things did not turn out so great for shareholders. It was a pretty negative result overall, with revenues of US$65m missing analyst predictions by 3.7%. Worse, the business reported a statutory loss of US$0.70 per share, much larger than the analysts had forecast prior to the result. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.
See our latest analysis for Maravai LifeSciences Holdings
Following last week's earnings report, Maravai LifeSciences Holdings' 14 analysts are forecasting 2025 revenues to be US$274.6m, approximately in line with the last 12 months. Earnings are expected to improve, with Maravai LifeSciences Holdings forecast to report a statutory profit of US$0.14 per share. Before this earnings report, the analysts had been forecasting revenues of US$296.0m and earnings per share (EPS) of US$0.14 in 2025. It's pretty clear that pessimism has reared its head after the latest results, leading to a weaker revenue outlook and a minor downgrade to earnings per share estimates.
The consensus price target fell 9.7% to US$10.10, with the weaker earnings outlook clearly leading valuation estimates. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. Currently, the most bullish analyst values Maravai LifeSciences Holdings at US$15.00 per share, while the most bearish prices it at US$7.00. This is a fairly broad spread of estimates, suggesting that analysts are forecasting a wide range of possible outcomes for the business.
Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. One thing that stands out from these estimates is that shrinking revenues are expected to moderate over the period ending 2025 compared to the historical decline of 3.0% per annum over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenue grow 6.6% per year. So it's pretty clear that, while it does have declining revenues, the analysts also expect Maravai LifeSciences Holdings to suffer worse than the wider industry.